Get the Stockscreener App
160.30
0.91%
1.44
After Hours:
160.30
Charles River Laboratories International Inc stock is traded at $160.30, with a volume of 588.58K.
It is up +0.91% in the last 24 hours and down -13.26% over the past month.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
See More
Previous Close:
$158.86
Open:
$159.83
24h Volume:
588.58K
Relative Volume:
0.63
Market Cap:
$7.72B
Revenue:
$4.02B
Net Income/Loss:
$-142.16M
P/E Ratio:
-54.22
EPS:
-2.9563
Net Cash Flow:
$518.49M
1W Performance:
+6.26%
1M Performance:
-13.26%
6M Performance:
-4.38%
1Y Performance:
+18.22%
1-Day Range:
$155.56
$163.42
1-Week Range:
$146.19
$163.42
52-Week Range:
$132.58
$228.88
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
160.30 | 7.65B | 4.02B | -142.16M | 518.49M | -2.9563 |
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | RBC Capital Mkts | Outperform |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-17-25 | Upgrade | Argus | Hold → Buy |
| Nov-06-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-06-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-02-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-23-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| May-14-25 | Upgrade | TD Cowen | Hold → Buy |
| May-08-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-04-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-03-25 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Jan-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-17-25 | Downgrade | UBS | Buy → Neutral |
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
Charles River Laboratories Inte (CRL) Stock Analysis: A 30% Upside Potential Amidst Healthcare Sector Dynamics - DirectorsTalk Interviews
Cell Banking Outsourcing Market: 16%+ CAGR (2026-2031), Expanding with Rising Demand for Biologics and Regenerative Medicine Services, Says Mordor Intelligence - GlobeNewswire Inc.
Is Charles River (CRL) Quietly Recasting Its Moat Around AI Pathology And Cell Therapy Services? - Yahoo Finance
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Should Higher Impairments and AI Investments Shape a New Capital Allocation Playbook for Charles River (CRL)? - simplywall.st
Charles River Laboratories (CRL) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
A Look At Charles River Laboratories (CRL) Valuation After Recent Share Price Weakness - simplywall.st
Inspired Announces CFO Transition - The Manila Times
Charles River Laboratories International Inc. stock underperforms Friday when compared to competitors - MSN
The 5 Most Interesting Analyst Questions From Charles River Laboratories’s Q1 Earnings Call - Yahoo Finance
Charles River Laboratories Tops Q3 Estimates, Tightens Full-Year Outlook - MSN
NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know - Yahoo Finance
Charles River Deepens Cell Therapy Role And Expands AI Pathology Platform - simplywall.st
Charles River (CRL) reliance on international sales: What investors need to know - MSN
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Director Nancy Andrews gifts Charles River (CRL) shares to trust - Stock Titan
Charles River Laboratories stock (US1591881009): Q1 earnings beat with updated FY guidance - AD HOC NEWS
Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions - BioSpace
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Charles River Laboratories stock (US1591881009): Shareholders approve 2026 incentive plan - AD HOC NEWS
Charles River Laboratories (CRL) Announces Approval of 2026 Long-Term Incentive Plan - GuruFocus
Director Steven Barg receives 1,438-share equity award at Charles River (NYSE: CRL) - Stock Titan
Charles River Labs (CRL) director receives 1,438-share equity award grant - Stock Titan
Director at Charles River (NYSE: CRL) receives 1,438-share stock grant - Stock Titan
Charles River Laboratories stock (US1591881009): Q1 earnings beat but FY2026 forecast cut - AD HOC NEWS
Number of shareholders of Charles River Laboratories International, Inc. – HAM:RV6 - TradingView
Charles River Laboratories International Inc (CRL) Stock Down 5. - GuruFocus
CRL Q1 Earnings & Revenues Top Estimates, Margins Crash, Stock Down - MSN
Charles River Labs Shareholders Approve New Incentive Plan - TipRanks
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Charles River (NYSE: CRL) investors approve 2026 incentive plan, pay and auditor - Stock Titan
Charles River Laboratories International, Inc. Approves Ratification of PricewaterhouseCoopers LLP as Independent Auditors - marketscreener.com
Charles River (NYSE: CRL) director Abraham Ceesay receives 1,438-share stock grant - Stock Titan
Charles River Labs (NYSE: CRL) director Martin Mackay receives new stock grants - Stock Titan
Director at Charles River (NYSE: CRL) gets 1,438-share equity grant - Stock Titan
Charles River (NYSE: CRL) director receives stock grants instead of fees - Stock Titan
Director at Charles River (NYSE: CRL) receives 1,438-share stock award - Stock Titan
Director at Charles River (NYSE: CRL) receives 1,973-share equity award - Stock Titan
Director Virginia M. Wilson (CRL) receives 1,438-share equity award at Charles River - Stock Titan
Director James Foster gets 1,860 Charles River (NYSE: CRL) shares - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Charles River (CRL) Enhances Digital Pathology Platform for Fast - GuruFocus
Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow - 01net
Charles River (CRL) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Charles River expands AI-enabled digital pathology platform By Investing.com - Investing.com Canada
Charles River Laboratories stock (US1591881009): Core business and market position - AD HOC NEWS
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.72%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):